Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MDCX Medicus Pharma	$1.94 -3.0%	$2.62	$1.80 ▼ $8.94	$34.56M	N/A	401,684 shs	310,578 shs
MRSN Mersana Therapeutics	$7.32 -4.4%	$7.69	$5.21 ▼ $70.75	$36.53M	0.83	101,299 shs	40,654 shs
OKUR OnKure Therapeutics	$2.75 -2.1%	$2.43	$1.70 ▼ $20.00	$37.21M	0.4	128,496 shs	37,314 shs
SNPX Synaptogenix	$5.82 -11.1%	$7.48	$1.84 ▼ $7.85	$8.09M	1.08	250,819 shs	429,835 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MDCX Medicus Pharma	0.00%	-12.61%	-21.14%	-20.82%	+193,999,900.00%
MRSN Mersana Therapeutics	0.00%	-5.55%	+6.86%	-14.64%	-80.35%
OKUR OnKure Therapeutics	0.00%	-2.83%	+24.43%	+10.44%	+274,999,900.00%
SNPX Synaptogenix	-11.08%	-23.92%	-13.65%	+136.59%	+62.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MDCX Medicus Pharma	1.6779 of 5 stars	3.8	0.0	0.0	0.0	1.9	0.8	0.0
MRSN Mersana Therapeutics	4.1028 of 5 stars	3.5	4.0	0.0	4.1	1.6	2.5	0.0
OKUR OnKure Therapeutics	2.854 of 5 stars	3.6	0.0	0.0	0.0	1.9	2.5	1.3
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	1,111.34% Upside
MRSN Mersana Therapeutics	3.00	Buy	$56.60	673.22% Upside
OKUR OnKure Therapeutics	3.14	Buy	$32.33	1,075.76% Upside
SNPX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SNPX, MDCX, MRSN, and OKUR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	OKUR OnKure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/14/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$250.00 ➝ $36.00
8/14/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$125.00 ➝ $30.00
8/13/2025	MRSN Mersana Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/13/2025	OKUR OnKure Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.18 per share	N/A
MRSN Mersana Therapeutics	$34.77M	1.05	N/A	N/A	($10.65) per share	-0.69
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$5.78 per share	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
MRSN Mersana Therapeutics	-$69.19M	-$14.62	N/A	N/A	N/A	-212.94%	-990.16%	-54.85%	11/12/2025 (Estimated)
OKUR OnKure Therapeutics	-$52.67M	-$4.80	N/A	N/A	N/A	N/A	-60.52%	-55.43%	11/6/2025 (Estimated)
SNPX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A

Latest SNPX, MDCX, MRSN, and OKUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	MRSN Mersana Therapeutics	-$3.75	-$4.08	-$0.33	-$4.87	$6.06 million	$3.06 million
8/12/2025	Q2 2025	OKUR OnKure Therapeutics	-$1.23	-$1.14	+$0.09	-$1.14	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
SNPX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MDCX Medicus Pharma	N/A	1.29	1.29
MRSN Mersana Therapeutics	N/A	1.35	1.35
OKUR OnKure Therapeutics	N/A	11.13	11.13
SNPX Synaptogenix	N/A	72.59	72.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MDCX Medicus Pharma	N/A
MRSN Mersana Therapeutics	93.92%
OKUR OnKure Therapeutics	90.98%
SNPX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
MDCX Medicus Pharma	11.20%
MRSN Mersana Therapeutics	13.00%
OKUR OnKure Therapeutics	2.30%
SNPX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MDCX Medicus Pharma	N/A	17.82 million	15.82 million	N/A
MRSN Mersana Therapeutics	150	4.99 million	4.34 million	Optionable
OKUR OnKure Therapeutics	N/A	13.53 million	13.22 million	N/A
SNPX Synaptogenix	4	1.39 million	1.35 million	Not Optionable

SNPX, MDCX, MRSN, and OKUR Headlines

Recent News About These Companies

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

July 1, 2025 | prnewswire.com

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

June 26, 2025 | prnewswire.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN Austin

June 26, 2025 | kxan.comK

Synaptogenix begins TAO acquisition as part of crypto treasury strategy

June 26, 2025 | uk.investing.com

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLA

June 26, 2025 | ktla.comK

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

June 24, 2025 | prnewswire.com

Synaptogenix Unveils TAO-Focused Crypto Treasury Plan

June 10, 2025 | livebitcoinnews.comL

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

June 9, 2025 | prnewswire.com

Synaptogenix Inc Ordinary Shares

January 3, 2025 | morningstar.comM

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

December 20, 2024 | prnewswire.com

Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary

October 7, 2024 | benzinga.com

Synaptogenix secures $5 million in preferred stock financing

September 13, 2024 | investing.com

Synaptogenix Announces $5.0 Million Financing

September 11, 2024 | prnewswire.com

SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024

August 16, 2024 | investorplace.com

Synaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord Injury

July 19, 2024 | markets.businessinsider.com

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

July 18, 2024 | prnewswire.com

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

June 26, 2024 | prnewswire.com

SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024

May 20, 2024 | investorplace.com

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024 | prnewswire.com

Synaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

April 24, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNPX, MDCX, MRSN, and OKUR Company Descriptions

Medicus Pharma NASDAQ:MDCX

$1.94 -0.06 (-3.00%)

As of 08/29/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Mersana Therapeutics NASDAQ:MRSN

$7.32 -0.34 (-4.44%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.33 +0.01 (+0.19%)

As of 08/29/2025 07:39 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

OnKure Therapeutics NASDAQ:OKUR

$2.75 -0.06 (-2.14%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.78 +0.02 (+0.91%)

As of 08/29/2025 04:50 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Synaptogenix NASDAQ:SNPX

$5.82 -0.73 (-11.08%)

As of 08/29/2025

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time